June 14, 2016
RealTime Dynamix™: Bone and Mineral Metabolism, June 2016
Monthly refresh for the US phosphate binder and secondary hyperparathyroidism market wth launch metrics for Auryxia and Velphoro with pre-launch insight on Parsabiv, Amgen’s IV calcimimetic. n=104 nephrologists
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices in Zug, Switzerland. We specialize in renal, autoimmune, neurologic and rare disease markets.
For more information contact:
Telephone: (800) 661-0571
Email: [email protected]
www.spherixglobalinsights.com